HUP0004747A3 - 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation - Google Patents

4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation

Info

Publication number
HUP0004747A3
HUP0004747A3 HU0004747A HUP0004747A HUP0004747A3 HU P0004747 A3 HUP0004747 A3 HU P0004747A3 HU 0004747 A HU0004747 A HU 0004747A HU P0004747 A HUP0004747 A HU P0004747A HU P0004747 A3 HUP0004747 A3 HU P0004747A3
Authority
HU
Hungary
Prior art keywords
carboxyamino
substituted
preparation
tetrahydroquinoline derivatives
tetrahydroquinoline
Prior art date
Application number
HU0004747A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU0004747D0 publication Critical patent/HU0004747D0/hu
Publication of HUP0004747A2 publication Critical patent/HUP0004747A2/hu
Publication of HUP0004747A3 publication Critical patent/HUP0004747A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0004747A 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation HUP0004747A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (3)

Publication Number Publication Date
HU0004747D0 HU0004747D0 (cg-RX-API-DMAC7.html) 2001-02-28
HUP0004747A2 HUP0004747A2 (hu) 2001-10-28
HUP0004747A3 true HUP0004747A3 (en) 2002-12-28

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004747A HUP0004747A3 (en) 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation

Country Status (44)

Country Link
US (1) US6313142B1 (cg-RX-API-DMAC7.html)
EP (1) EP1125929B1 (cg-RX-API-DMAC7.html)
JP (1) JP3579345B2 (cg-RX-API-DMAC7.html)
KR (1) KR100408177B1 (cg-RX-API-DMAC7.html)
CN (1) CN1173953C (cg-RX-API-DMAC7.html)
AP (1) AP2000002011A0 (cg-RX-API-DMAC7.html)
AR (1) AR029775A1 (cg-RX-API-DMAC7.html)
AT (1) ATE315028T1 (cg-RX-API-DMAC7.html)
AU (1) AU784694B2 (cg-RX-API-DMAC7.html)
BG (1) BG105009A (cg-RX-API-DMAC7.html)
BR (1) BR0005636A (cg-RX-API-DMAC7.html)
CA (1) CA2327029C (cg-RX-API-DMAC7.html)
CO (1) CO5261552A1 (cg-RX-API-DMAC7.html)
CY (1) CY1104989T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20004407A3 (cg-RX-API-DMAC7.html)
DE (1) DE60025317T2 (cg-RX-API-DMAC7.html)
DK (1) DK1125929T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3079A1 (cg-RX-API-DMAC7.html)
EA (1) EA003668B1 (cg-RX-API-DMAC7.html)
EE (1) EE200000659A (cg-RX-API-DMAC7.html)
ES (1) ES2254109T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022798B (cg-RX-API-DMAC7.html)
GT (1) GT200000190A (cg-RX-API-DMAC7.html)
HN (1) HN2000000203A (cg-RX-API-DMAC7.html)
HR (1) HRP20000804A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0004747A3 (cg-RX-API-DMAC7.html)
ID (1) ID28489A (cg-RX-API-DMAC7.html)
IL (1) IL139849A (cg-RX-API-DMAC7.html)
IS (1) IS5715A (cg-RX-API-DMAC7.html)
MA (1) MA25223A1 (cg-RX-API-DMAC7.html)
NO (1) NO20006039L (cg-RX-API-DMAC7.html)
NZ (1) NZ508509A (cg-RX-API-DMAC7.html)
OA (1) OA11494A (cg-RX-API-DMAC7.html)
PA (1) PA8503801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20010913A1 (cg-RX-API-DMAC7.html)
PL (1) PL344208A1 (cg-RX-API-DMAC7.html)
SG (1) SG102603A1 (cg-RX-API-DMAC7.html)
SK (1) SK17792000A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN00230A1 (cg-RX-API-DMAC7.html)
TW (1) TW591016B (cg-RX-API-DMAC7.html)
UA (1) UA65615C2 (cg-RX-API-DMAC7.html)
UY (1) UY26451A1 (cg-RX-API-DMAC7.html)
YU (1) YU71500A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006947B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
DE60323954D1 (de) * 2002-04-11 2008-11-20 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp-aktivität und der wirksamkeit der behandlung von herzerkrankungen
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
WO2004078730A2 (en) * 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CA2519432C (en) * 2003-03-17 2009-06-09 Japan Tobacco Inc. Pharmaceutical compositions comprising cetp inhibitors and a water-insoluble concentration-enhancing additive for the treatment of cardiovascular disease
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP2098512A1 (en) * 2003-10-08 2009-09-09 Eli Lilly & Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
EP1861372A1 (en) * 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (cg-RX-API-DMAC7.html) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
DK1125929T3 (da) 2006-04-03
ES2254109T3 (es) 2006-06-16
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
IS5715A (is) 2001-05-31
HUP0004747A2 (hu) 2001-10-28
IL139849A (en) 2006-10-31
KR100408177B1 (ko) 2003-12-01
MA25223A1 (fr) 2001-07-02
BG105009A (en) 2001-11-30
CZ20004407A3 (cs) 2002-06-12
AU7178900A (en) 2001-05-31
CN1302800A (zh) 2001-07-11
AU784694B2 (en) 2006-06-01
EA200001129A2 (ru) 2001-06-25
ID28489A (id) 2001-05-31
GEP20022798B (en) 2002-09-25
CY1104989T1 (el) 2010-03-03
NO20006039D0 (no) 2000-11-29
EP1125929B1 (en) 2006-01-04
OA11494A (en) 2004-05-07
TNSN00230A1 (fr) 2005-11-10
DZ3079A1 (fr) 2004-10-24
UY26451A1 (es) 2001-06-29
JP2001163859A (ja) 2001-06-19
KR20010052012A (ko) 2001-06-25
AR029775A1 (es) 2003-07-16
EA200001129A3 (ru) 2001-10-22
GT200000190A (es) 2002-04-27
HU0004747D0 (cg-RX-API-DMAC7.html) 2001-02-28
HRP20000804A2 (en) 2001-06-30
CO5261552A1 (es) 2003-03-31
DE60025317T2 (de) 2006-08-03
EE200000659A (et) 2001-08-15
HK1038007A1 (en) 2002-03-01
DE60025317D1 (de) 2006-03-30
SK17792000A3 (sk) 2002-10-08
IL139849A0 (en) 2002-02-10
CA2327029C (en) 2005-08-09
HN2000000203A (es) 2001-06-13
AP2000002011A0 (en) 2000-12-31
US6313142B1 (en) 2001-11-06
NO20006039L (no) 2001-05-31
NZ508509A (en) 2001-06-29
CN1173953C (zh) 2004-11-03
ZA200006947B (en) 2002-05-27
EP1125929A1 (en) 2001-08-22
BR0005636A (pt) 2001-07-17
TW591016B (en) 2004-06-11
ATE315028T1 (de) 2006-02-15
PA8503801A1 (es) 2002-07-30
UA65615C2 (uk) 2004-04-15
CA2327029A1 (en) 2001-05-30
SG102603A1 (en) 2004-03-26
YU71500A (sh) 2003-02-28
PE20010913A1 (es) 2001-09-10
EA003668B1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
HUP0004747A3 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation
HUP0201225A3 (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agent and process for their preparation
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
IL147923A0 (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
IL147925A0 (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
HUP0102084A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0103224A3 (en) Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
HRP20010454B1 (en) 1,2-annelated quinoline derivatives
GB9823873D0 (en) 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
HUP0105136A3 (en) Amide derivatives, process for their preparation and medicaments containing them
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HUP0101375A3 (en) Novel cephalotaxane derivatives, process for their preparation and intermediates
HUP9800555A3 (en) 3,3-diphenylallylamine derivatives and process for their preparation
HUP0004884A3 (en) Process for preparing 1,4-dihydropyridine derivatives
HUP0104620A3 (en) 2-phenylpyran-4-one derivatives, process for their preparation and medicaments containing them
HUP0104819A3 (en) Chroman derivatives, their use intermediate and process for their preparation
AU7446900A (en) Thioalkylamine derivatives and process for the preparation thereof
HUP0101234A3 (en) Betha-carboline derivatives, process for their preparation and pharmaceutical compositions thereof
HUP0003861A3 (en) Quinolin-4-yl derivatives, process for producing them and pharmaceutical compositions containing them
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
HUP0204572A3 (en) Substituierte bisindolylmaleinimide derivatives, process for their preparation and use and pharmaceutcial compositions containing them
GR3035834T3 (en) Benzoxazindione derivatives, process for their preparation and their use
AU6870500A (en) Process for the preparation of 2,3-dihydroazepine derivatives
HUP0103311A3 (en) Pyrrolo-izoquinoline, -naphtyridine and benzo [c] pyrrolo-azepine derivatives, process for their preparation and pharmaceutical compositions thereof
HUP0203421A3 (en) Process for preparing 10,11-methanobenzosuberane derivatives and their intermediates and processes for preparation thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees